Cogniscreen

Boston, MA, US

Precision Medicine/DiagnosticsBootstrapped

Cogniscreen operates as Cognimark, a neurology AI platform for dementia detection and differential diagnosis. It leverages proprietary machine learning models developed through multi-million dollar funded research at Boston University and MIT.

Shareable draft

Check out Cogniscreen on @MedStartr Today Cogniscreen operates as Cognimark, a neurology AI platform for dementia detection and differential diagnosis. It leverages proprietary machine learning models developed through multi-million dollar funded research at Boston University and MIT. #AlzheimerSDiseaseDementia #PrecisionMedicineDiagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/y4dlT61D9Tk

Get Involved in Cogniscreen

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Problem Statement

Cogniscreen addresses the challenge of accurately diagnosing dementia etiologies and stratifying risk in cognitively impaired individuals, aiming to improve patient outcomes and physician efficiency.

Core Technology

Cogniscreen's core technology is a proprietary multimodal deep learning model, developed over years of research, for AI-based differential diagnosis and risk stratification of cognitively impaired individuals.

Key Differentiators

Published research in Nature Medicine (2024); Published research in iScience (2023); Published research in Nature Communications (2022); Published research in Brain (2020); Integrated with EHR platforms Athena and eClinicalWorks; Live deployments across multiple healthcare sites; Dataset growing beyond 100,000 patients; Focus on clinical trial recruitment optimization

Clinical Focus

Neurology; Cognitive Impairment

Company Info

Business Model: B2B SaaS
Website: www.cognimark.ai/

Disease Areas

Alzheimer's & Dementia

Technologies

Machine LearningDeep LearningMultimodal DataAI & Machine Learning

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Cogniscreen?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.